Abstract 1578: MTBhsp70 fusion protein targeting mesothelin augments tumor specific T cell responses and prolongs survival in a murine model of ovarian cancer

2012 ◽  
Author(s):  
Jianping Yuan ◽  
Pierre Leblanc ◽  
Satoshi Kashiwagi ◽  
Jean Nezivar ◽  
Elda Righi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
T Cell ◽  
Fusion Protein ◽  
Murine Model ◽  
Protein Targeting ◽  
T Cell Responses ◽  
Cell Responses

A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer

2008 ◽  
Vol 31 (4) ◽  
pp. 420-430 ◽  
Author(s):  
Kimberly A. Chianese-Bullock ◽  
William P. Irvin ◽  
Gina R. Petroni ◽  
Cheryl Murphy ◽  
Mark Smolkin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
T Cell ◽  
T Cell Responses ◽  
Advanced Stage ◽  
Cell Responses

scholarly journals Activated leucocyte cell adhesion molecule (ALCAM/CD166) regulates T cell responses in a murine model of food allergy

2018 ◽  
Vol 192 (2) ◽  
pp. 151-164 ◽  
Author(s):  
Y. S. Kim ◽  
M. N. Kim ◽  
K. E. Lee ◽  
J. Y. Hong ◽  
M. S. Oh ◽  
...  
Keyword(s):  
Food Allergy ◽  
Cell Adhesion ◽  
T Cell ◽  
Adhesion Molecule ◽  
Murine Model ◽  
Cell Adhesion Molecule ◽  
T Cell Responses ◽  
Cell Responses

Regulation of T cell responses by BTLA: Functional analysis using a soluble BTLAIg fusion protein

2004 ◽  
Vol 2004 (Fall) ◽  
Author(s):  
Bernd Lepenies ◽  
Bernhard Fleischer ◽  
Thomas Jacobs
Keyword(s):  
Functional Analysis ◽  
T Cell ◽  
Fusion Protein ◽  
T Cell Responses ◽  
Cell Responses

scholarly journals Polyfunctional T-Cell Responses Are Disrupted by the Ovarian Cancer Ascites Environment and Only Partially Restored by Clinically Relevant Cytokines

PLoS ONE ◽  
2010 ◽  
Vol 5 (12) ◽  
pp. e15625 ◽  
Author(s):  
Eric Tran ◽  
Julie S. Nielsen ◽  
Darin A. Wick ◽  
Alvin V. Ng ◽  
Lisa D. S. Johnson ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
T Cell ◽  
T Cell Responses ◽  
Cell Responses

Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection

2002 ◽  
Vol 4 (8) ◽  
pp. 805-813 ◽  
Author(s):  
Anita R. Schnapp ◽  
Christopher S. Eickhoff ◽  
Julio Scharfstein ◽  
Daniel F. Hoft
Keyword(s):  
T Cell ◽  
Trypanosoma Cruzi ◽  
Murine Model ◽  
T Cell Responses ◽  
Cell Responses ◽  
Cruzi Infection

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

2018 ◽  
Vol 10 (436) ◽  
pp. eaao5931 ◽  
Author(s):  
Janos L. Tanyi ◽  
Sara Bobisse ◽  
Eran Ophir ◽  
Sandra Tuyaerts ◽  
Annalisa Roberti ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
T Cell ◽  
T Cell Responses ◽  
Recurrent Ovarian Cancer ◽  
Autologous Tumor ◽  
Serious Adverse Events ◽  
Cell Responses ◽  
Cell Immunity ◽  
Dc Vaccine ◽  
Personalized Cancer

We conducted a pilot clinical trial testing a personalized vaccine generated by autologous dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC), which was injected intranodally in platinum-treated, immunotherapy-naïve, recurrent ovarian cancer patients. OCDC was administered alone (cohort 1, n = 5), in combination with bevacizumab (cohort 2, n = 10), or bevacizumab plus low-dose intravenous cyclophosphamide (cohort 3, n = 10) until disease progression or vaccine exhaustion. A total of 392 vaccine doses were administered without serious adverse events. Vaccination induced T cell responses to autologous tumor antigen, which were associated with significantly prolonged survival. Vaccination also amplified T cell responses against mutated neoepitopes derived from nonsynonymous somatic tumor mutations, and this included priming of T cells against previously unrecognized neoepitopes, as well as novel T cell clones of markedly higher avidity against previously recognized neoepitopes. We conclude that the use of oxidized whole-tumor lysate DC vaccine is safe and effective in eliciting a broad antitumor immunity, including private neoantigens, and warrants further clinical testing.

Sign in / Sign up

Export Citation Format

Share Document